2021
-
Highlights from the Program Chair: Monday, April 12
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
-
Liquid biopsies hold promise for the future of cancer care
Presenters Caroline Dive, BPharm, PhD, Alberto Bardelli, PhD, and Sarah-Jane Dawson, MBBS, PhD, discussed different uses for this evolving field.
-
Forum considers when the right time is to utilize CAR-T therapies
(From left) Crystal L. Mackall, MD, Hagop M. Kantargian, MD, and Carl H. June, MD, PhD, FAACR, discussed how to decide between monoclonal antibodies, CAR-T therapies, or a combination.
-
Panel explores ongoing controversy of p-values in scientific research
(From left) Steven Goodman, MD, MHS, PhD, Mi-Ok Kim, PhD, and Motomi Mori, PhD, discussed current schools of thought regarding their use or misuse in studies.
-
Opening Ceremony: AACR CEO praises strength of cancer community amid challenging times
“Now, more than ever, it is imperative that our innovative work continues, because patients with cancer around the world are counting on us,” said AACR CEO Margaret Foti, PhD, MD (hc).
-
Leading researchers to discuss their work into understanding the tumor-host ecosystem
Monday’s plenary features presentations from (clockwise, from left) Serena Nik-Zainal, MD, PhD, Ross L. Levine, MD, Jérôme Galon, PhD, and Garry P. Nolan, PhD.
-
Plenary explores chromosomal instability’s role in cancer treatment
(Clockwise, top left) Samuel F. Bakhoum, MD, PhD, Karlene A. Cimprich, PhD, Stephen P. Jackson, PhD, and David Pellman, PhD, discussed its viability as a novel therapy target.
-
First Clinical Trials Plenary features practice-changing data from phase III trials
Updates on phase III trials came from (clockwise, top left) Matthew J. Matasar, MD, Jessica Hassel, MD, Patrick M. Forde, MBBCh, and Georgina V. Long, PhD, MBBS.
-
Daily Highlights for Sunday, April 11
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
-
CD40 agonist primes T-cell response to treat pancreatic cancer, early trial results show
(Clockwise, from top left) Katelyn T. Byrne, PhD, Brett G.M. Hughes, MSci, MBBS, Sanaz N. Ghafouri, MD, Jason Alan Chesney, MD, PhD, and Richard S. Finn, MD, will present during the session.